Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2026 Filed Oct 8, 2026 21:31 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000085 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,993 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year Read SEC document |
| October 07, 2026 Filed Oct 8, 2026 21:31 UTC |
Farrell Michael J.Director · Chairman and CEO
|
SaleResMed Common Stock | 4,991 | $226.33 | $1,129,637.49 |
DisclosureSEC source: 0000943819-26-000085 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 479,803 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price. Read SEC document |
| October 07, 2026 Filed Oct 8, 2026 21:31 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000085 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 484,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 10:40 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000052 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,984 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 10:40 UTC |
Farrell Michael J.Director · Chairman and CEO
|
SaleResMed Common Stock | 4,991 | $222.44 | $1,110,190.55 |
DisclosureSEC source: 0000943819-26-000052 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,256 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $220.680 - $225.390. The price reported above reflects the weighted average sale price. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 10:40 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000052 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 10:30 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 970 | $234.73 | $227,688.10 |
DisclosureSEC source: 0000943819-26-000050 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,803 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. Read SEC document |
| August 14, 2026 Filed Oct 2, 2026 00:08 UTC |
Bloomer AaronChief Financial Officer
|
GrantResMed Common Stock | 9,072 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-26-000073 · form4.xml · nonDerivative · entry 1 Bloomer Aaron · CIK 0002019003 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,072 F1 · kind: Represents performance-based restricted stock units granted on June 1, 2026. The RSUs were earned on August 14, 2026, when the compensation and leadership development committee certified that the applicable performance metrics were met. RSUs vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 14, 2026 Filed Oct 2, 2026 00:19 UTC |
Farrell Michael J.Director · Chairman and CEO
|
GrantResMed Common Stock | 13,547 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-26-000075 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 479,803 F1 · kind: Represents performance-based restricted stock units granted on November 20, 2025. The shares were earned on August 14, 2026, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 14, 2026 Filed Oct 2, 2026 00:23 UTC |
Rider Michael JGlobal General Counsel
|
GrantResMed Common Stock | 3,230 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-26-000076 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,718 F1 · kind: Represents performance-based restricted stock units granted on November 20, 2025. The RSUs were earned on August 14, 2026, when the compensation and leadership development committee certified that the applicable performance metrics were met. RSUs vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 14, 2026 Filed Oct 2, 2026 00:27 UTC |
Leong JustinChief Product Officer
|
GrantResMed Common Stock | 6,461 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-26-000077 · form4.xml · nonDerivative · entry 1 Leong Justin · CIK 0001825782 · Chief Product Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,489 F1 · kind: Represents performance-based restricted stock units granted on November 20, 2025. The RSUs were earned on August 14, 2026, when the compensation and leadership development committee certified that the applicable performance metrics were met. RSUs vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 10:30 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000043 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,975 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 10:30 UTC |
Farrell Michael J.Director · Chairman and CEO
|
SaleResMed Common Stock | 4,991 | $205.69 | $1,026,596.29 |
DisclosureSEC source: 0000943819-26-000043 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,256 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $202.410 - $204.160. The price reported above reflects the weighted average sale price. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 10:30 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000043 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| August 05, 2026 Filed Aug 6, 2026 18:29 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 8,000 | $225.00 | $1,800,000.00 |
DisclosureSEC source: 0000943819-26-000040 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,773 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 11:40 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000038 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,966 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 11:40 UTC |
Farrell Michael J.Director · Chairman and CEO
|
SaleResMed Common Stock | 4,991 | $218.55 | $1,090,770.57 |
DisclosureSEC source: 0000943819-26-000038 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,223 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $216.772 - $219.700. The price reported above reflects the weighted average sale price. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 11:40 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000038 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 18:26 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000035 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,957 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 18:26 UTC |
Farrell Michael J.Director · Chairman and CEO
|
SaleResMed Common Stock | 4,991 | $193.96 | $968,064.34 |
DisclosureSEC source: 0000943819-26-000035 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,256 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $192.605 - $194.715. The price reported above reflects the weighted average sale price. F3 · balance_after: Includes 32.671 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 18:26 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000035 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 19:45 UTC |
Rider Michael JGlobal General Counsel
|
Tax withholdingResMed Common Stock | 268.742 | $190.57 | $51,214.16 |
DisclosureSEC source: 0000943819-26-000033 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,488 F1 · shares: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 06/01/2023. F2 · balance_after: Includes 66.0288 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan. Read SEC document |
| May 07, 2026 Filed May 11, 2026 11:33 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000030 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,948 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| May 07, 2026 Filed May 11, 2026 11:33 UTC |
Farrell Michael J.Director · Chairman and CEO
|
SaleResMed Common Stock | 4,991 | $207.82 | $1,037,232.61 |
DisclosureSEC source: 0000943819-26-000030 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,223 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $206.45 - $210.47. The price reported above reflects the weighted average sale price. Read SEC document |
| May 07, 2026 Filed May 11, 2026 11:33 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000030 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 15:44 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000021 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,939 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 15:44 UTC |
Farrell Michael J.Director · Chairman and CEO
|
SaleResMed Common Stock | 4,991 | $225.50 | $1,125,486.47 |
DisclosureSEC source: 0000943819-26-000021 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,223 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $222.5643 - $227.96. The price reported above reflects the weighted average sale price. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 15:44 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000021 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 17:52 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 2,000 | $225.00 | $450,000.00 |
DisclosureSEC source: 0000943819-26-000019 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,773 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 11:29 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,000 | $224.31 | $224,310.00 |
DisclosureSEC source: 0000943819-26-000020 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,495 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 12:29 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000016 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,930 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 12:29 UTC |
Farrell Michael J.Director · Chairman and CEO
|
SaleResMed Common Stock | 4,991 | $251.03 | $1,252,901.71 |
DisclosureSEC source: 0000943819-26-000016 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,223 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $246.83 - $253.09. The price reported above reflects the weighted average sale price. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 12:29 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000016 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 19:51 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 2,000 | $260.22 | $520,440.00 |
DisclosureSEC source: 0000943819-26-000014 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,773 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:29 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,000 | $254.30 | $254,300.00 |
DisclosureSEC source: 0000943819-26-000013 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,495 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 18:33 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000011 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,921 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 18:33 UTC |
Farrell Michael J.Director · Chairman and CEO
|
SaleResMed Common Stock | 4,991 | $273.78 | $1,366,436.48 |
DisclosureSEC source: 0000943819-26-000011 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,223 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $270.25 - $276.35. The price reported above reflects the weighted average sale price. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 18:33 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000011 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 16:07 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 2,000 | $251.31 | $502,620.00 |
DisclosureSEC source: 0000943819-26-000010 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,773 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 16:05 UTC |
Rider Michael JGlobal General Counsel
|
SaleResMed Common Stock | 50 | $260.00 | $13,000.00 |
DisclosureSEC source: 0000943819-26-000009 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,691 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 28, 2025. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 20:06 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,000 | $257.03 | $257,030.00 |
DisclosureSEC source: 0000943819-26-000008 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,495 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 20:23 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000003 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,912 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 20:23 UTC |
Farrell Michael J.Director · Chairman and CEO
|
SaleResMed Common Stock | 4,991 | $248.46 | $1,240,065.36 |
DisclosureSEC source: 0000943819-26-000003 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,223 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $246.801 - $249.969. The price reported above reflects the weighted average sale price. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 20:23 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000003 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 12:33 UTC |
FARRELL PETER CDirector
|
SaleResMed Common Stock | 2,000 | $248.83 | $497,660.00 |
DisclosureSEC source: 0000943819-26-000004 · form4.xml · nonDerivative · entry 1 FARRELL PETER C · CIK 0001186102 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,773 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 18:18 UTC |
Rider Michael JGlobal General Counsel
|
SaleResMed Common Stock | 50 | $241.75 | $12,087.50 |
DisclosureSEC source: 0000943819-26-000001 · form4.xml · nonDerivative · entry 1 Rider Michael J · CIK 0001982205 · Global General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,741 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 28, 2025. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 22:27 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 1,000 | $241.75 | $241,750.00 |
DisclosureSEC source: 0000943819-26-000002 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,495 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 20:17 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-25-000187 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,903 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 20:17 UTC |
Farrell Michael J.Director · Chairman and CEO
|
SaleResMed Common Stock | 4,991 | $251.41 | $1,254,795.79 |
DisclosureSEC source: 0000943819-25-000187 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,223 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $249.63 - $255.775. The price reported above reflects the weighted average sale price. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 20:17 UTC |
Farrell Michael J.Director · Chairman and CEO
|
Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-25-000187 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.